局部进展期胃癌围手术期免疫检查点抑制剂的应用策略  

Application strategies of immune checkpoint inhibitors in perioperative therapy of locally advanced gastric cancer

作　　者：程向东[1] Cheng Xiangdong(Department of Gastric Surgery,Zhejiang Cancer Hospital,Hangzhou 310022,China)

机构地区：[1]浙江省肿瘤医院胃外科,杭州310022

出　　处：《中华消化外科杂志》2024年第3期339-344,共6页Chinese Journal of Digestive Surgery

基　　金：浙江省上消化道肿瘤诊治中心项目(JBZX⁃202006)。

摘　　要：目前免疫治疗已成为晚期胃癌的标准治疗,其在局部进展期胃癌围手术期治疗中的探索也是近几年的热点。进展期胃癌即使接受外科手术治疗,5年生存率仍偏低,疗效欠佳。术后辅助化疗可延长局部进展期胃癌患者的生存时间,新辅助化疗可使肿瘤降期,延长生存时间。虽然免疫检查点抑制剂目前在局部进展期胃癌围手术期治疗中广泛应用,但同时也面临着应用指征、适用人群、疗效相关并发症处理等诸多问题。笔者梳理目前进展期胃癌免疫检查点抑制剂相关临床研究结果,并结合临床实践经验,深入阐述其应用现状和临床问题。At present,immunotherapy has become the standard treatment for advanced gastric cancer.The exploration of immunotherapy in perioperative therapy of locally advanced gastric cancer is a hotspot in recent years.The 5‐year survival rate of advanced gastric cancer is still low even after surgical treatment.Postoperative adjuvant chemotherapy can improve the survival time of patients with locally advanced gastric cancer,while neoadjuvant chemotherapy can reduce tumor progression and prolong survival time.Although immune checkpoint inhibitors are currently widely used in the perioperative treatment of locally advanced gastric cancer,they also face many problems such as indications for application,target audience,and management of efficacy related complications.The author summarizes the current clinical research results related to immune checkpoint inhibitors in advanced gastric cancer,and elaborates on the current application status and clinical issues based on own clinical experience.

关 键 词：胃肿瘤 免疫检查点抑制剂 围手术期 疗效 不良反应 

分 类 号：R735.2[医药卫生—肿瘤]